newsfilter
← Latest News
Business Wire·

Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update

IMNM
  • Immunome received FDA acceptance of the varegacestat NDA with a PDUFA target action date of April 28, 2027.
  • The EMA validated Immunome's MAA for varegacestat in October 2026 for treating desmoid tumors.
  • Updated Phase 1 data for IM-1021 showed a 53% objective response rate across 19 B-cell non-Hodgkin lymphoma patients.
  • Immunome expects to present an updated IM-1021 dataset at the ASH meeting on December 14, 2026.
  • The company received IND clearance for IM-1340 in September 2026 & expects to initiate its Phase 1 trial by year-end 2026.
  • The first patient was dosed in the Phase 1 trial for IM-1617 in June 2026.
  • The first patient was dosed in the Phase 1 trial for IM-3050 in July 2026.
  • Immunome expects to submit an IND for IM-1335 in late 2026.
  • Cash, cash equivalents, & marketable securities totaled $461.6 million as of September 30, 2026.
  • The company's current cash position is expected to fund operations into 2028.
  • Research & development expenses for the quarter ended September 30, 2026, were $69.5 million.
  • General & administrative expenses for the quarter ended September 30, 2026, were $20.9 million.
  • Immunome reported a net loss of $85.8 million for the quarter ended September 30, 2026.